证券日报网讯 8月1日晚间，富士莱发布公告称，截至2025年7月31日，公司通过股票回购专用证券账户 以集中竞价交易方式累计回购公司股份数量为400，000股，占公司目前总股本的0.4363%。 （文章来源：证券日报） ...

格隆汇8月1日丨富士莱(301258.SZ)公布，截至2025年7月31日，公司通过股票回购专用证券账户以集中 竞价交易方式累计回购公司股份数量为400,000股，占公司目前总股本的0.4363%，最高成交价为35.72 元/股，最低成交价为33.04元/股，使用资金总额为1381.5655万元(不含交易费用)。 ...

富士莱（301258）公告，截至2025年7月31日，公司通过股票回购专用证券账户以集中竞价交易方式累 计回购公司股份数量为40万股，占公司目前总股本的0.4363%，最高成交价为35.72元/股，最低成交价 为33.04元/股，使用资金总额为1381.57万元(不含交易费用)。公司实施回购符合相关法律法规及既定的 回购股份方案。 ...

二、其他说明 公司回购股份的时间、回购股份价格及集中竞价交易的委托时段符合《深圳 证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定。 证券代码：301258 证券简称：富士莱 公告编号：2025-036 苏州富士莱医药股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召开 第四届董事会第十九次会议、第四届监事会第十八次会议，审议通过了《关于使 用自有资金回购公司股份方案的议案》，同意公司使用自有资金通过集中竞价交 易方式回购公司人民币普通股（A 股），并在未来适宜时机用于股权激励计划或 员工持股计划。本次回购股份资金总额不低于人民币 2,000 万元（含本数）且不 超过人民币 4,000 万元（含本数），回购价格不超过人民币 40.00 元/股（含）。 回购期限自公司董事会审议通过本次回购股份方案之日起不超过 12 个月。具体 内容详见公司于 2025 年 7 月 7 日在巨潮资讯网（www.cninfo.com.cn）上披露的 ...

Group 1 - The core point of the article is that Fujifilm (富士莱) has announced its collaboration with Hengrui Medicine (恒瑞医药) on an active pharmaceutical ingredient (API) project, which includes Eribulin and Apatinib Mesylate [1] Group 2 - The collaboration focuses on the development of specific APIs, indicating a strategic partnership in the pharmaceutical sector [1] - The mention of Eribulin and Apatinib Mesylate highlights the company's involvement in oncology-related drug development [1]

格隆汇7月30日丨富士莱(301258.SZ)于投资者互动平台表示，公司与恒瑞医药合作的原料药项目有艾瑞 昔布、甲磺酸阿帕替尼。 ...

Group 1: Private Equity Performance - The top private equity firms as of mid-2025 include Nengjing Investment, Tongben Investment, Luyuan Private Equity, Chenyao Private Equity, and Youbo Capital, with Nengjing Investment achieving an average return of 114.65% across its products [1] - The average return for the top 100 private equity products reached 24.08% in the first half of 2025, with a total of 593 products under management [1] - Among the top-performing products, "Nengjing Value Selection No. 2" achieved a remarkable return of 281.59% [1] Group 2: Fund Manager Performance - A total of 513 private equity fund managers reported performance, with an average return of 10.56%, significantly outperforming the Shanghai and Shenzhen indices [2] - 73 fund managers achieved returns exceeding 20%, with the top 10 fund managers having a performance threshold of approximately 18.5% [2] - The leading fund managers include Lu Hang from Fusheng Asset, Yin Tao from Wobo Investment, and Wang Yiping from Evolutionary Asset [2] Group 3: Market Trends and Foreign Investment - As of the end of Q2 2025, foreign capital in A-shares reached a market value of 2.28 trillion yuan, an increase of approximately 54.8 billion yuan from the previous quarter [7] - Notable foreign investments include significant increases in holdings of Ningde Times and Heng Rui Pharmaceutical, while Jinpu Titanium Industry has become a new favorite among foreign investors [7] - Some stocks, such as Degute, have seen foreign investors and social security funds exit, indicating selective interest in the market [7] Group 4: Strategic Partnerships - M&G Investments has partnered with Guotai Junan Securities to enhance access for Chinese investors to global markets, focusing on information sharing and asset management [9] - The collaboration aims to develop joint brand fixed-income investment solutions targeting the Asian market, with plans to launch within months [9] - M&G anticipates that the Chinese asset management industry will reach a scale of 40.4 trillion USD by 2030, highlighting the growth potential in this sector [9] Group 5: Regulatory Issues - Two financial apps, "Cai Da Cai Ri Sheng" and "Yin Tai Zhang Yi Bao," were reported for violating personal information collection regulations [19] - The violations included failing to obtain user consent for sharing personal information and not providing clear privacy policy notifications [19] - The regulatory scrutiny reflects ongoing efforts to enforce personal information protection in the financial sector [19]

Group 1 - Several A-share listed companies, including Shijia Photon, Oriental Bio, and Maiwei Bio, have disclosed their latest top ten shareholders due to buyback activities, revealing adjustments by well-known fund managers [1][2] - Notable fund managers such as Jin Zicai, Wan Minyuan, and Jin Xiaofei have made significant adjustments in their holdings, with Jin Zicai's funds entering the top ten shareholders of Shijia Photon after a 130% increase in its stock price in the first half of the year [2] - Foreign institutions like Barclays, UBS, and JPMorgan have increased their stakes in several A-share companies, indicating growing foreign interest in the market [3] Group 2 - The A-share market is experiencing structural opportunities amid internal and external factors, with a potential upward trend in the short term [4] - The overall investment attractiveness of the Chinese capital market is improving, with an increase in stock buybacks and dividend distributions, which are highly valued by foreign investors [4][5] - Economic indicators show signs of recovery in consumption, investment, and exports, with expectations for a more accommodative monetary policy in the coming quarters [5]

证券代码：301258 证券简称：富士莱 公告编号：2025-035 苏州富士莱医药股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 2025 年 7 月 10 日，公司通过股票回购专用证券账户以集中竞价交易方式首 次回购公司股份数量为 5,000 股，占公司目前总股本的 0.0055%，最高成交价为 34.46 元/股，最低成交价为 34.28 元/股，使用资金总额为 171,940.00 元（不含交 易费用）。公司实施回购符合相关法律法规及既定的回购股份方案。 二、其他说明 公司回购股份的时间、回购股份价格及集中竞价交易的委托时段符合《深圳 证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定。 （一）公司未在下列期间回购公司股份： 1、自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； 2、中国证监会和深交所规定的其他情形。 （二）公司以集中竞价交易方式回购股份的，符合下列要求： 苏州富士莱医药股份有限公司（以下简称"公司"）于 2025 年 7 月 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-033 苏州富士莱医药股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召 开第四届董事会第十九次会议、第四届监事会第十八次会议，审议通过了《关于 使用自有资金回购公司股份方案的议案》，具体内容详见公司于 2025 年 7 月 7 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于使用自有资金回购公司股 份方案的公告》（公告编号：2025-032）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，现将公司董事会公告回购股份决议的前一个交 易日（即 2025 年 7 月 4 日）登记在册的前十名股东和前十名无限售条件股东的 名称及持股数量、持股比例公告如下： | 序号 | 股东名称 | 持有数量（股） | 占公司总股本比 例 | | --- | --- | --- | --- | | 1 | 苏州市富士莱技术服务发展中心（有限 | 55,200, ...